{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:12:58Z","timestamp":1748491978367},"reference-count":27,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2012]]},"DOI":"10.1536\/ihj.53.244","type":"journal-article","created":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T22:27:53Z","timestamp":1344292073000},"page":"244-248","source":"Crossref","is-referenced-by-count":3,"title":["Combination of Antihypertensive Therapy in The Elderly, Multicenter Investigation (CAMUI) Trial"],"prefix":"10.1536","volume":"53","author":[{"given":"Nobuyuki","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiolog, Asahikawa Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Saijo","sequence":"additional","affiliation":[{"name":"Division of Community Medicine and Epidemiology, Department of Health Science, Asahikawa Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Department of Cardiolog, Asahikawa Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.29.143"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ogihara T, Kikuchi K, Matsuoka H, <i>et al<\/i>. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.","DOI":"10.1038\/hr.2009.34"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mancia G, De Backer G, Dominiczak A, <i>et al<\/i>. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4: 42-50.","DOI":"10.1016\/j.jash.2010.02.005"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00213-9"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.30.729"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Brenner BM, Cooper ME, de Zeeuw D, <i>et al<\/i>. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.","DOI":"10.1056\/NEJMoa011161"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dahl&ouml;f B, Devereux RB, Kjeldsen SE, <i>et al<\/i>. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.30.831"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00653.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006; 1: 229-35. (Review)","DOI":"10.2215\/CJN.00840805"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chobanian AV, Bakris GL, Black HR, <i>et al<\/i>. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jamerson K, Weber MA, Bakris GL, <i>et al<\/i>. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.","DOI":"10.1056\/NEJMoa0806182"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.102"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71082-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-93.","DOI":"10.1001\/archinte.160.5.685"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Mann JF, Schmieder RE, Dyal L, <i>et al<\/i>. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1-10.","DOI":"10.7326\/0003-4819-151-1-200907070-00122"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. So WY, Kong AP, Ma RC, <i>et al<\/i>. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29: 2046-52.","DOI":"10.2337\/dc06-0248"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03086-4"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70143-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Freitag MH, Peila R, Masaki K, <i>et al<\/i>. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke 2006; 37: 33-7.","DOI":"10.1161\/01.STR.0000196941.58869.2d"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(00)00259-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Li NC, Lee A, Whitmer RA, <i>et al<\/i>. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.","DOI":"10.1136\/bmj.b5465"},{"key":"24","unstructured":"25. Schrader J, L&uuml;ders S, Diener HC, <i>et al<\/i>. Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study). Med Klin (Munich) 2008; 103: 491-9. (German)"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Fogari R, Mugellini A, Zoppi A, <i>et al<\/i>. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003; 17: 781-5.","DOI":"10.1038\/sj.jhh.1001613"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Ohrui T, Tomita N, Sato-Nakagawa T, <i>et al<\/i>. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-5.","DOI":"10.1212\/01.WNL.0000140705.23869.E9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Zhu D, Shi J, Zhang Y, <i>et al<\/i>. Central angiotensin II stimulation promotes <i>&beta;<\/i> amyloid production in Sprague Dawley rats. PLoS One 2011; 6: e16037.","DOI":"10.1371\/journal.pone.0016037"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/53\/4\/53_244\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T07:11:28Z","timestamp":1618816288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/53\/4\/53_244\/_article"}},"subtitle":["Rationale and Design"],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.53.244","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}